Back to Top
Antibodies in Clinic / Clinical Trials
-
February 26, 2026
Apitegromab: A Myostatin Inhibitor for Spinal Muscular Atrophy
... -
February 25, 2026
Bentracimab: The First-in-Class Reversal Agent for Ticagrelor
... -
A Researcher’s Guide to Narsoplimab: Structure, Mechanism of Action, and Clinical Efficacy in TA-TMA
January 07, 2026Narsoplimab: Structure, Mechanism of Action, and Clinical Efficacy in TA-TMA
... -
December 22, 2025
Depemokimab: Structure, Mechanism of Action, and Clinical Efficacy in Eosinophilic Diseases
... -
December 03, 2025
Picankibart: Structure, Mechanism of Action, and Clinical Efficacy in Psoriasis
... -
A Researcher’s Guide to Sibeprenlimab: Structure, Mechanism of Action, and Clinical Efficacy in IgAN
November 30, 2025Sibeprenlimab: Structure, Mechanism of Action, and Clinical Efficacy in IgAN
... -
A Researcher’s Guide to Trastuzumab Botidotin: Structure, Mechanism of Action, and Clinical Efficacy
October 28, 2025Trastuzumab Botidotin: Structure, Mechanism of Action, and Clinical Efficacy
... -
August 07, 2025
FDA Approval Spotlight: Linvoseltamab — A BCMA x CD3 Bispecific for Multiple Myeloma
In July 2025, the FDA granted accelerated approval to linvoseltamab, a BCMA × CD3 T-cell engaging bispecific antibody, for the treatment of ...
-
November 05, 2024
Understanding Modern Bispecific Antibodies: Mechanism, Applications, and Clinical Development Status
Introduction
Bispecific...
-
October 09, 2024
A Comprehensive Overview of Antibody Engineering Mutations
Antibody engineering has revolutionized the development of therapeutic antibodies by introducing mutations that modulate various aspects of antibody function. This overview provides a concise summary of key mutation strategies in antibody engineering, including their benefits and challenges.
...
